Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports

25-09-2024 | Migraine | Review

Review on the Burden of Episodic Migraine and Utilization of Patient Reported Outcome Measures

Authors: Mohammad Ismail Ehsani-Nia, Avi Wannon, Jessica Ailani

Published in: Current Neurology and Neuroscience Reports

Login to get access

Abstract

Purpose of Review

Migraine affects a large portion of the world’s population. Migraine encompasses a broad range of symptoms, with broad reaching ramifications in the form of Health-Related Quality of Life (HRQoL) factors. In our review we sought to understand the aspects encompassing the burden of disease on both an individual and population level. Furthermore, we reviewed the development and incorporation of Patient Reported Outcome Measures (PROM), questionnaires that assess HRQoL in real time, in how they have been incorporated in clinical research up to now and how they can be utilized in clinical practice moving forward.

Recent Findings

It has been shown that there is much heterogeneity within the field in PROM development processes as well as their utilization in episodic migraine (EM) clinical trials. Furthermore, they are inconsistently used in clinical practice.

Summary

Among the most commonly used PROMs, the MSQv2.1 is among the most valid and reliable. Beyond that, it also shows promise to help in guidance of clinical management of migraine.
Literature
1.
Ford JH, Foster SA, Nichols RM, Tockhorn-Heidenreich A, Ye W, Jackson J, Cotton SA real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe. Journal of Patient-Reported Outcomes. 2020 https://​doi.​org/​10.​1186/​s41687-020-00221-w.
2.
3.
Digre K. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache: J Head Face Pain 2018;59:1–18
4.
Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: Migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clinic Proc. 2009;84:422–35.CrossRef
5.
6.
7.
8.
9.
Rai N, Bitswa R, Singh R, Pakhre A, Parauha D. Factors associated with delayed diagnosis of Migraine: A hospital-based cross-sectional study. J Family Med Primary Care. 2019;8:1925.CrossRef
10.
11.
Viticchi G, Silvestrini M, Falsetti L, Lanciotti C, Cerqua R, Luzzi S, Provinciali L, Bartolini M. Time delay from onset to diagnosis of Migraine. Headache:  J Head Face Pain 2010;51:232–236.
12.
Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84:688–95.CrossRefPubMedPubMedCentral
13.
14.
Ford J, Nichols RM, Ye W, Tockhorn-Heidenreich A, Cotton S, Jackson J. Patient-reported outcomes for migraine in the US and Europe: Burden associated with multiple preventive treatment failures. ClinicoEconomics Outcomes Res. 2021;13:647–60.CrossRef
15.
Wijeratne T, Grisold W, Dodick D, Carroll W. World Brain Day 2019: Migraine, the painful truth. Lancet Neurology. 2019;18:914.CrossRefPubMed
16.
Linde M, Dahlöf C. Attitudes and burden of disease among self-considered migraineurs — a nation-wide population-based survey in Sweden. Cephalalgia. 2004;24:455–65.CrossRefPubMed
17.
Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: Measuring disability in headache disorders with WHO’s classification of functioning, Disability and Health (ICF). J Headache Pain. 2005;6:429–40.CrossRefPubMedPubMedCentral
18.
Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of Migraine. QJM. 1996;89:77–84.CrossRefPubMed
19.
Abu Bakar N, Tanprawate S, Lambru G, Torkamani M, Jahanshahi M, Matharu M. Quality of life in primary headache disorders: A Review. Cephalalgia. 2015;36:67–91.CrossRefPubMed
20.
Diener H-C, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for Controlled Trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40:1026–44.CrossRefPubMed
21.
Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: Migraine-specific quality-of-life questionnaire Further Investigation of the Factor Structure. PharmacoEconomics. 1998;13:707–17.CrossRefPubMed
22.
Rendas-Baum R, Bloudek LM, Maglinte GA, Varon SF. The psychometric properties of the migraine-specific quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Quality Life Res. 2012;22:1123–33.CrossRef
23.
Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlöf CGH, Dowson A, Tepper S. A Six-Item Short-Form Survey for Measuring Headache Impact: The HIT-6. Quality Life Res. 2003;12:963–74.CrossRef
24.
Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (hit-6TM) across episodic and chronic migraine. Cephalalgia. 2010;31:357–67.CrossRefPubMed
25.
Stewart W, Lipton R, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19:107–14.CrossRefPubMed
26.
Geisser M, Clauw D, Strand V, Gendreau M, Palmer R, Williams D. Contributions of change in clinical status parameters to patient global impression of change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain. 2010;149:373–378.
27.
McGinley JS, Houts CR, Nishida TK, Buse DC, Lipton RB, Goadsby PJ, Dodick DW, Wirth RJ. Systematic review of outcomes and endpoints in preventive migraine clinical trials. Headache: J Head Face Pain 2021;61:253–262.
28.
Haywood KL, Mars TS, Potter R, Patel S, Matharu M, Underwood M. Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs). Cephalalgia. 2017;38:1374–86.CrossRefPubMedPubMedCentral
29.
Burch R. Preventive migraine treatment. CONTINUUM: Lifelong Learning in Neurology 2021;27:613–632.
30.
31.
Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P (2021) In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain. https://​doi.​org/​10.​1186/​s10194-021-01366-9.
Metadata
Title
Review on the Burden of Episodic Migraine and Utilization of Patient Reported Outcome Measures
Authors
Mohammad Ismail Ehsani-Nia
Avi Wannon
Jessica Ailani
Publication date
25-09-2024
Publisher
Springer US
Keywords
Migraine
Headache
Published in
Current Neurology and Neuroscience Reports
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-024-01379-2

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more
Image Credits